AcelRx receives positive CHMP opinion for DZUVEO(TM) for management of acute moderate to severe pain in medically monitored settings
DZUVEO is AcelRx's second developed sublingual sufentanil-based product to receive positive CHMP opinion, with Zalviso® already approved
Resubmission of New Drug Application for DSUVIA (known as DZUVEO in Europe) to the FDA in the U.S. is planned f... Biopharmaceutical, Drug Delivery, Regulatory AcelRx Pharmaceuticals, DZUVEO, DSUVIA, sufentanil, sublingual
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news